$CABA is the next $SLS—400%+ Upside to $15 🚀
If you missed the $SLS run to $15, stop chasing and load up on Cabaletta Bio ($CABA) around $3.10 before the herd catches on.
If you exited SLS and are looking for a place to park your profits, then CABA is 100% for you.
They are pioneering the holy grail of biotech right now: preconditioning-free CAR-T for autoimmune diseases (think a literal one-and-done "CURE" button for Lupus and Sclerosis without any nasty chemo).
Here's why:
- Eli Lilly Backing & Funding Secured: They just closed a massive $150M offering backed by heavy-hitters like Eli Lilly and Bain Capital. Cash runway is officially secured through mid-2027, meaning the near-term dilution overhang is completely gone.
- The Cellares Manufacturing Moat: The biggest bottleneck in cell therapy is scaling. $CABA just inked a 10-year commercial agreement with Cellares to use their automated "Cell Shuttle," ensuring they can mass-produce these therapies for thousands of patients at the lowest cost in the industry.
- Pivotal PHASE 3 Myositis Trial (Now): Their registrational PHASE 3 myositis study is actively advancing right now. The early data showed 100% durability up to 1.5 years off all other drugs, and they are aggressively marching toward a 2027 BLA filing and FDA approval.
- The Holy Grail—PC-Free Lupus Data (H2 2026): We are getting longer-term readouts from their preconditioning-free (PC-free) Lupus and PV cohorts this half of the year. If they prove they can safely expand CAR-T cells and reset the immune system without toxic chemo prep, the total addressable market explodes.
You have Big Pharma cash, automated manufacturing secured, a pivotal trial running, and a massive pipeline update dropping in H2 2026.
Wall Street consensus targets sit right at $15 (with Cantor Fitzgerald aiming for $30). It’s a beaten-down, high-short-interest spring waiting to coil. Get in under $4, watch the data drop, and ride the CAR-T hype train straight to $15. 💎🙌